Trials / Terminated
TerminatedNCT01786395
Phase III Efficacy and Safety Clinical Study of UF-021 for Treatment of Retinitis Pigmentosa
Phase III Clinical Study of UF-021 for Retinitis Pigmentosa - Evaluation for a Comparative Double Masked Placebo Controlled Study Period and a Continuous Administration Period
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 202 (actual)
- Sponsor
- R-Tech Ueno, Ltd. · Industry
- Sex
- All
- Age
- 20 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study is a multicenter trial performed in Japan, consisting of a comparative study period and a continuous administration period. Effect of 0.15% UF-021 eye drops on improvement in central retinal sensitivity with HFA will be verified in 52 weeks comparative study period by a placebo-controlled, double-masked study in patients with retinitis pigmentosa. The safety of same eye drops will also be examined in 52 weeks continuous administration period, in all the patients who completed the comparative study period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | UF-021 | |
| DRUG | Placebo |
Timeline
- Start date
- 2013-03-01
- Primary completion
- 2015-04-01
- First posted
- 2013-02-08
- Last updated
- 2016-01-29
Locations
34 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT01786395. Inclusion in this directory is not an endorsement.